TNSN97044A1 - Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant. - Google Patents

Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.

Info

Publication number
TNSN97044A1
TNSN97044A1 TNTNSN97044A TNSN97044A TNSN97044A1 TN SN97044 A1 TNSN97044 A1 TN SN97044A1 TN TNSN97044 A TNTNSN97044 A TN TNSN97044A TN SN97044 A TNSN97044 A TN SN97044A TN SN97044 A1 TNSN97044 A1 TN SN97044A1
Authority
TN
Tunisia
Prior art keywords
preparation
methods
compositions containing
intermediates
quinoxalinedone
Prior art date
Application number
TNTNSN97044A
Other languages
English (en)
Inventor
John Bull David
Lee Carr Christopher
Jonathan Fray Michael
Colette Louise Gautier Elisabeth
Eric Mowbray Charles
Stobie Alan
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of TNSN97044A1 publication Critical patent/TNSN97044A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSES DE FORMULE I : DANS LAQUELLE R, R1 ET R2 SONT CHOISIS ENTRE H ET DIVERS RADICAUX ORGANIQUES AINSI QUE LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES. DES PROCEDES POUR LEUR PREPARATION, DES COMPOSITIONS LES CONTENANT, ET DES INTERMEDIAIRES UTILISES DANS LEUR SYNTHESE SONT PROPOSES. APPLICATION : UTILISATION DE CES COMPOSES, ANTAGONISTES DES RECEPTEURS DE NMDA, POUR LE TRAITEMENT DE DIVERSES MALADIES NEUROLOGIQUES.
TNTNSN97044A 1996-03-09 1997-03-05 Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant. TNSN97044A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9605027.3A GB9605027D0 (en) 1996-03-09 1996-03-09 Quinoxalinediones

Publications (1)

Publication Number Publication Date
TNSN97044A1 true TNSN97044A1 (fr) 2005-03-15

Family

ID=10790134

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97044A TNSN97044A1 (fr) 1996-03-09 1997-03-05 Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.

Country Status (42)

Country Link
US (1) US6376490B1 (fr)
EP (1) EP0885212B1 (fr)
JP (1) JP3110467B2 (fr)
KR (1) KR100288099B1 (fr)
CN (1) CN1103770C (fr)
AP (1) AP767A (fr)
AR (1) AR006119A1 (fr)
AT (1) ATE208773T1 (fr)
AU (1) AU717972B2 (fr)
BG (1) BG63340B1 (fr)
BR (1) BR9707851A (fr)
CA (1) CA2248366C (fr)
CO (1) CO4770976A1 (fr)
CZ (1) CZ292792B6 (fr)
DE (1) DE69708269T2 (fr)
DK (1) DK0885212T3 (fr)
DZ (1) DZ2188A1 (fr)
EA (1) EA001730B1 (fr)
ES (1) ES2163742T3 (fr)
GB (1) GB9605027D0 (fr)
HN (1) HN1998000034A (fr)
HR (1) HRP970132A2 (fr)
HU (1) HUP9900975A3 (fr)
ID (1) ID18112A (fr)
IL (1) IL125491A (fr)
IS (1) IS4811A (fr)
MA (1) MA26422A1 (fr)
NO (1) NO984058L (fr)
NZ (1) NZ331060A (fr)
OA (1) OA10850A (fr)
PE (2) PE43398A1 (fr)
PL (1) PL329032A1 (fr)
PT (1) PT885212E (fr)
SI (1) SI0885212T1 (fr)
SK (1) SK283467B6 (fr)
TN (1) TNSN97044A1 (fr)
TR (1) TR199801782T2 (fr)
TW (1) TW454004B (fr)
UY (1) UY24482A1 (fr)
WO (1) WO1997032873A1 (fr)
YU (2) YU39698A (fr)
ZA (1) ZA971987B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69827614T2 (de) * 1997-02-27 2005-11-10 Pfizer Inc. Chinoxalindionen
AP982A (en) 1997-02-27 2001-07-16 Pfizer Quinoxalinediones.
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
DE10005150A1 (de) 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
KR100776119B1 (ko) * 2000-05-19 2007-11-16 아스텔라스세이야쿠 가부시키가이샤 트리아졸 유도체
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2005006945A2 (fr) * 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Procedes de traitement de troubles neurologiques et composes utiles a cet effet
MY145368A (en) * 2004-01-13 2012-01-31 Nissan Chemical Ind Ltd Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof
EP1713101B1 (fr) 2004-02-06 2012-10-31 Yamaguchi University Électrode pour dispositif de stockage d'énergie et procédé de production de cette électrode
JP2007223901A (ja) * 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
US20060211739A1 (en) * 2005-02-08 2006-09-21 Arturo Perez-Medrano Use of selective P2X7 receptor antagonists
WO2007112347A1 (fr) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
EP2089383B1 (fr) 2006-11-09 2015-09-16 Probiodrug AG Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
EP2150248A4 (fr) * 2007-01-16 2011-06-29 Univ Johns Hopkins Antagonistes de récepteur de glutamate et procédés d'utilisation
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
ES2533484T3 (es) 2007-04-18 2015-04-10 Probiodrug Ag Derivados de tiourea como inhibidores de la glutaminil ciclasa
WO2008143019A1 (fr) * 2007-05-17 2008-11-27 Semiconductor Energy Laboratory Co., Ltd. Dérivé de triazole et élément émetteur de lumière, dispositif émetteur de lumière et dispositif électronique utilisant le dérivé de triazole
DK2475428T3 (en) 2009-09-11 2015-09-28 Probiodrug Ag Heterocyclic derivatives as glutaminylcyklaseinhibitorer
WO2011107530A2 (fr) 2010-03-03 2011-09-09 Probiodrug Ag Nouveaux inhibiteurs
CN102791704B (zh) 2010-03-10 2015-11-25 前体生物药物股份公司 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
CA2900300A1 (fr) * 2013-02-07 2014-08-14 Merck Patent Gmbh Derives d'acetylene substitues et leur utilisation a titre de modulateurs allosteriques positifs du mglur4
EP3461819B1 (fr) 2017-09-29 2020-05-27 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase
CN111548320B (zh) * 2019-10-09 2023-03-24 贵州大学 一类1,3,4-噁二唑酰肼类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2150417T3 (es) * 1990-11-06 2000-12-01 Yamanouchi Pharma Co Ltd Derivados de pirazina fusionados.
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE69827614T2 (de) * 1997-02-27 2005-11-10 Pfizer Inc. Chinoxalindionen

Also Published As

Publication number Publication date
NO984058D0 (no) 1998-09-03
YU39698A (sh) 1999-03-04
DE69708269T2 (de) 2002-07-25
TW454004B (en) 2001-09-11
PT885212E (pt) 2002-02-28
AP767A (en) 1999-09-29
DK0885212T3 (da) 2002-03-25
CZ286498A3 (cs) 1999-07-14
IL125491A0 (en) 1999-03-12
HUP9900975A2 (hu) 1999-07-28
CA2248366C (fr) 2002-06-04
CN1213369A (zh) 1999-04-07
SI0885212T1 (en) 2002-02-28
AU717972B2 (en) 2000-04-06
AR006119A1 (es) 1999-08-11
SK121498A3 (en) 2000-10-09
ZA971987B (en) 1998-09-07
CZ292792B6 (cs) 2003-12-17
ATE208773T1 (de) 2001-11-15
PE58199A1 (es) 1999-06-11
NZ331060A (en) 2000-01-28
EA001730B1 (ru) 2001-08-27
PE43398A1 (es) 1998-08-29
EP0885212A1 (fr) 1998-12-23
GB9605027D0 (en) 1996-05-08
NO984058L (no) 1998-11-06
JPH11506123A (ja) 1999-06-02
DE69708269D1 (de) 2001-12-20
TR199801782T2 (xx) 1998-12-21
HRP970132A2 (en) 1998-06-30
KR100288099B1 (ko) 2001-05-02
SK283467B6 (sk) 2003-08-05
HN1998000034A (es) 1999-02-09
CN1103770C (zh) 2003-03-26
JP3110467B2 (ja) 2000-11-20
EP0885212B1 (fr) 2001-11-14
PL329032A1 (en) 1999-03-01
CA2248366A1 (fr) 1997-09-12
IL125491A (en) 2003-07-06
DZ2188A1 (fr) 2002-12-02
US6376490B1 (en) 2002-04-23
BG63340B1 (bg) 2001-10-31
AU2023197A (en) 1997-09-22
ES2163742T3 (es) 2002-02-01
ID18112A (id) 1998-03-05
KR19990087614A (ko) 1999-12-27
WO1997032873A1 (fr) 1997-09-12
UY24482A1 (es) 2000-09-29
MA26422A1 (fr) 2004-12-20
OA10850A (en) 2001-08-16
BR9707851A (pt) 1999-07-27
BG102760A (en) 1999-09-30
YU41199A (sh) 2001-09-28
IS4811A (is) 1998-07-27
AP9700947A0 (en) 1997-04-30
HUP9900975A3 (en) 2001-12-28
CO4770976A1 (es) 1999-04-30
EA199800702A1 (ru) 1999-04-29

Similar Documents

Publication Publication Date Title
TNSN97044A1 (fr) Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
TNSN96075A1 (fr) N-(indole-2-carbonyl) - beta- alaninamides substitues et leurs derives, servant d'agents antidiabetiques
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97144A1 (fr) Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97078A1 (fr) Derives d'indole nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99162A1 (fr) Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TNSN98150A1 (fr) Derives d'acides aryloxyarylsulfonylaminohydroxamiques ; procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98237A1 (fr) Composes azapolycycliques a noyau aryle condense, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01077A1 (fr) Derives de tropane nouveaux, procede pour leur preparation et compositions les contenant
MA25035A1 (fr) Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
TNSN99142A1 (fr) Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation.
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
TNSN02021A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
TNSN96172A1 (fr) Composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant